Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Drugs Made In America Acq...

    NASDAQ: DMAA · Real-Time Price · USD
    10.27
    0.00 (0.00%)
    At close: Oct 03, 2025, 3:39 PM
    10.29
    0.19%
    After-hours: Oct 03, 2025, 04:04 PM EDT

    Drugs Made In America Acquisition Ordinary Shares Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024
    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024
    Revenue
    		 n/a n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a n/a n/a
    Gross Profit
    		 n/a n/a n/a n/a n/a
    Operating Income
    		 -608.05K -476.19K -145.26K -144.98K -54.93
    Interest Income
    		 4.01M 1.59M n/a n/a n/a
    Pretax Income
    		 3.4M 1.11M -145.26K -144.98K -54.93
    Net Income
    		 3.4M 1.11M -145.26K -144.98K -54.93
    Selling & General & Admin
    		 608.05K 476.19K 145.26K 144.98K 54.93
    Research & Development
    		 n/a n/a n/a n/a n/a
    Other Expenses
    		 n/a n/a n/a n/a n/a
    Operating Expenses
    		 608.05K 476.19K 145.26K 144.98K 54.93
    Interest Expense
    		 n/a n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a n/a
    Cost & Expenses
    		 608.05K 476.19K 145.26K 144.98K 54.93
    Income Tax Expense
    		 n/a n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 33.52M 9.61K 8.57K 8.57K 8.57K
    Shares Outstanding (Diluted)
    		 33.52M 25.51K 8.57K 8.57K 8.57K
    EPS (Basic)
    		 130.54 130.47 -0.04 -0.01 -0.01
    EPS (Diluted)
    		 49.21 49.14 -0.04 -0.01 -0.01
    EBITDA
    		 -607.77K -475.85K -144.93K -144.93K n/a
    EBIT
    		 -608.05K -476.19K -145.26K -144.98K -54.93
    Depreciation & Amortization
    		 279.88 334.81 334.81 54.93 54.93

    Add to Watchlist